United States 115th Congress Status: In Committee 1 D cosponsors

S 207 — SALTS Act

Last action — Placed on Senate Legislative Calendar under General Orders. Calendar No. 472.

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill died with 115th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.

Summary

Synthetic Abuse and Labeling of Toxic Substances Act of 2017 or the SALTS Act (Sec. 2) This bill amends the Controlled Substances Act to set forth factors that may be considered as evidence to determine whether a controlled substance analogue is intended for human consumption. (Under current law, a controlled substance analogue that is intended for human consumption is treated as a schedule I controlled substance. A schedule I controlled substance is a drug, substance, or chemical that: has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.)

Bill Text

What changed in the latest version

13 added · 6 removed

Plain-language change summary

The text adds the names of additional senators who are co-sponsoring the bill to the introduction section. This change is significant because it may indicate broader support for the bill among members of the Senate, which could affect its consideration and potential for passage.

→
Previous
Latest
207 Introduced in Senate (IS)] <DOC> 115th CONGRESS 1st Session S.
207 Reported in Senate (RS)] <DOC> Calendar No.
472 115th CONGRESS 2d Session S.
Tillis, and Mr.
Tillis, Mr.
Warner) introduced the following bill;
Warner, Mr.
which was read twice and referred to the Committee on the Judiciary _______________________________________________________________________ A BILL To amend the Controlled Substances Act relating to controlled substance analogues.
Hatch, Ms.
Hassan, Mr.
Rubio, Mr.
Markey, Mr.
Kennedy, Ms.
Smith, and Mr.
Coons) introduced the following bill;
which was read twice and referred to the Committee on the Judiciary June 19, 2018 Reported by Mr.
Grassley, without amendment _______________________________________________________________________ A BILL To amend the Controlled Substances Act relating to controlled substance analogues.
<all>
Calendar No.
472 115th CONGRESS 2d Session S.
207 _______________________________________________________________________ A BILL To amend the Controlled Substances Act relating to controlled substance analogues.
_______________________________________________________________________ June 19, 2018 Reported without amendment
⬇ Download PDF
View plain text versions (2)

How this bill changes current law

3 changes Share ↗

Compared against current U.S. Code AI-generated reading aid — verify against the official bill.

The bill amends the definition and considerations for determining whether a controlled substance analogue is intended for human consumption under the Controlled Substances Act.

  • 21 U.S.C. § 813

    A controlled → (a) In General.--A controlled

    This change adds a heading for clarity and structure in the statute.

  • 21 U.S.C. § 813

    (b) Determination.--In determining whether a controlled substance analogue was intended for human consumption under subsection (a), evidence related to the following factors may be considered, along with all other relevant evidence: (1) The marketing, advertising, and labeling of the substance. (2) The known efficacy or usefulness of the substance for the marketed, advertised, or labeled purpose. (3) The difference between the price at which the substance is sold and the price at which the substance it is purported to be or advertised as is normally sold. (4) The diversion of the substance from legitimate channels and the clandestine importation, manufacture, or distribution of the substance. (5) Whether the defendant knew or should have known the substance was intended to be consumed by injection, inhalation, ingestion, or any other immediate means.

    This addition introduces a new subsection outlining specific factors that may be considered in determining if a controlled substance analogue was intended for human consumption.

  • 21 U.S.C. § 813

    (c) Limitation.--For purposes of this section, the existence of evidence that a substance was not marketed, advertised, or labeled for human consumption shall not preclude the Government from establishing, based on all the evidence, that the substance was intended for human consumption.

    This new limitation subsection clarifies that the lack of marketing for human consumption does not automatically mean the substance was not intended for human use.

Action History

  1. Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.

  2. Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.

  3. Placed on Senate Legislative Calendar under General Orders. Calendar No. 472.

  4. Committee on the Judiciary. Ordered to be reported without amendment favorably.

  5. Committee on the Judiciary Subcommittee on Crime and Terrorism. Hearings held.

  6. Introduced in Senate

  7. Read twice and referred to the Committee on the Judiciary.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 546 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (546)

546 members have not signed on to this bill.

Show all 546 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

taxation
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does S 207 do?
Synthetic Abuse and Labeling of Toxic Substances Act of 2017 or the SALTS Act (Sec. 2) This bill amends the Controlled Substances Act to set forth factors that may be considered as evidence to determine whether a controlled substance analogue is intended for human consumption. (Under current law, a controlled substance analogue that is intended for human consumption is treated as a schedule I controlled substance. A schedule I controlled substance is a drug, substance, or chemical that: has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.)
Who sponsors S 207?
S 207 is sponsored by Klobuchar, Amy (Democratic).
What is the current status of S 207?
This bill died with 115th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track S 207?
Track S 207 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on S 207

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of S 207

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →